Breast Cancer Clinical Trial

The Effects of Red Wine and White Wine on Blood Estrogen and Progesterone Levels

Summary

Healthy pre-menopausal women will be recruited in order to test the effects of red wine and white wine on blood estrogen and progesterone levels. The women will be randomized and rotated through two different treatments (red wine, white wine). Estrone and estradiol are hormones in the category of estrogens. It is known that the bodies of both men and women may convert (or aromatize) a certain amount of naturally occurring testosterone into estrogen. Aromatase inhibitors have been used to prevent this conversion, or aromatization, of testosterone into estrogen, in the treatment of estrogen-dependent breast cancer in women. This inhibition leads to a marked decrease in estrogen (estradiol and estrone) levels. Naturally occurring aromatase inhibitors include grapes, grape juice, and red, but not white wine. The aromatase inhibitory effects are attributed to wine phytochemicals and not to alcohol. Based upon this information, the investigators will monitor the estrogen levels at various phases in the menstrual cycles of women since hormone levels naturally vary throughout the menstrual cycle. Several epidemiologic studies have found that there is a correlation with moderate to high levels of alcohol consumption and breast cancer. Therefore, study participants will be asked to drink only a eight ounces of wine which should have minimal or no risk for the development of breast cancer.

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

female
pre-menopausal with regular ovulatory cycles for 12 months prior to the study
willingness and ability to participate in study requiring alcohol consumption
in general good health
BMI of 18.5-35
on regular, unrestricted diet
not currently, or within the past 3 months, using oral contraceptives or other hormone replacement therapy

Exclusion Criteria:

male
irregular menstrual cycles or vasomotor symptoms within the last 12 months
pregnant (or breast feeding)
any hormone therapy including phytoestrogens, oral contraceptives, SERMs (selective estrogen receptor modulators), or androgens (or precursors) for three months prior to the study
history of alcohol abuse
history of any estrogen-dependent neoplasia
high intake of dietary soy products
Minors < age 21 years

Study is for people with:

Breast Cancer

Estimated Enrollment:

44

Study ID:

NCT00572351

Recruitment Status:

Completed

Sponsor:

Cedars-Sinai Medical Center

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There is 1 Location for this study

See Locations Near You

Cedars-Sinai Women's Heart Center
Los Angeles California, 90048, United States

How clear is this clinincal trial information?

Study is for people with:

Breast Cancer

Estimated Enrollment:

44

Study ID:

NCT00572351

Recruitment Status:

Completed

Sponsor:


Cedars-Sinai Medical Center

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.

Please confirm you are a US based health care provider:

Yes, I am a health care Provider No, I am not a health care provider